

To Whom it May Concern,

I am a physician assistant in dermatology that has practiced in Iowa since 2009. I am writing to request that during your consideration of Eucrisa coverage that you would strongly consider requiring only one topical steroid pass through in order to obtain Eucrisa. With nine years of experience, I have treated hundreds of atopic dermatitis and eczema patients. Eucrisa is an invaluable medication. Often when a patient has presented to my clinic they know that a steroid can help but they are fearful of long term use and rightfully so. Their condition is chronic and as we are all aware, long term use of topical steroids can cause thinning of the skin irreversibly. Eucrisa has no limit on duration of use, it can be applied to all areas affected with no risk of atrophy and no black box warnings making it my preferred medication for management. I do not want to have to provide a topical immunomodulator for what I anticipate being only temporary use. Often atopic dermatitis affects a wide body surface area and even if the topical immunomodulator was effective, I will not allow them to use that over a wide area for extended maintenance therapy. Please allow patients to get Eucrisa easily, quickly, and affordably early in their atopic dermatitis treatment.